Computational biology is essential in the process of translating biological knowledge into clinical practice, as well as in the understanding of biological phenomena based on the resources and technologies originating from the clinical environment. One such key contribution of computational biology is the discovery of biomarkers for predicting clinical outcomes using 'omic' information. This process involves the predictive modelling and integration of different types of data and knowledge for screening, diagnostic or prognostic purposes. Moreover, this requires the design and combination of different methodologies based on statistical analysis and machine learning. This article introduces key computational approaches and applications to biomarker discovery based on different types of 'omic' data. Although we emphasize applications in cardiovascular research, the computational requirements and advances discussed here are also relevant to other domains. We will start by introducing some of the contributions of computational biology to translational research, followed by an overview of methods and technologies used for the identification of biomarkers with predictive or classification value. The main types of 'omic' approaches to biomarker discovery will be presented with specific examples from cardiovascular research. This will include a review of computational methodologies for single-source and integrative data applications. Major computational methods for model evaluation will be described together with recommendations for reporting models and results. We will present recent advances in cardiovascular biomarker discovery based on the combination of gene expression and functional network analyses. The review will conclude with a discussion of key challenges for computational biology, including perspectives from the biosciences and clinical areas.
TRANSLATIONAL BIOMEDICAL RESEARCH AND COMPUTATIONAL BIOLOGY
Computational biology comprises the application of different computational methodologies and technologies to understand biological systems at different organizational and complexity scales. It ranges from molecules and cells, through patients, to ecosystems. This typically requires the analysis, visualization, modelling and integration of different types of data and information based on advances derived from areas such as database design, data mining and mathematical simulations. Translational research refers to the incorporation of biological knowledge into medical practice for disease prevention, diagnosis or treatment. This is paired with the transference of questions and data generated during routine clinical practice into basic biological research. Thus, it is evident that computational biology plays a crucial role at the interface of such a bidirectional, iterative knowledge discovery and communication process.
On the clinical side (the bedside) practical questions and requirements relating to routine practice are asked and biological samples (i.e. fluids and solid tissue) are obtained from patients. Moreover, a great variety of data describing environmental exposures (e.g. life style), clinical outcomes after disease diagnosis and treatment response are digitally stored. Some of such phenotypic information will then become the 'prediction' targets in laboratory and computational investigations (e.g. diagnostic classes). On the laboratory side (the bench) samples are processed to extract data in the form of 'omic' resources, e.g. gene sequences, transcripts, etc. Traditionally, it is on this side where hypotheses are initially generated based on clinical questions.
Computational biology is not only an important driving force at each side, but also it is the connecting bridge between the clinical and basic biological sciences. This is typically achieved through the implementation of computational infrastructures and large-scale data analysis. But, perhaps more importantly, computational biology offers possibilities to refine hypotheses generated at the bench, as well as to generate novel insights that go beyond the single-gene hypothesis-making paradigm. Figure 1 illustrates the interplay between clinical, laboratory and computational research environments, and highlights typical computational biology tasks.
Computational biology significantly contributes to four major application domains in translational biomedical research (Figure 2 ). One such area, the development of new disease biomarkers for diagnostic and prognostic applications is the focus of this review, with an emphasis on the discovery of new prediction and classification models through integrative data mining. The next section overviews recent advances in this area through the analysis of different types of 'omic' data. This will be followed by discussions of computational methodologies that exploit integrative prediction and classification techniques, with a focus on cardiovascular research. After offering recommendations for evaluating and reporting biomarker research findings, we will conclude with an overview of key challenges and emerging requirements in biomarker discovery.
COMPUTATIONAL BIOLOGY AND BIOMARKER DEVELOPMENT
A biomarker may be defined as 'a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention' [1] . Biomarkers may be categorized into: 'Type 0' biomarkers, which are used to estimate the emergence or development of a disease; 'Type 1' biomarkers, which measure responses to therapeutic interventions; and 'Type 2' biomarkers, which may be used as surrogate clinical endpoints. The 'Type 0' category covers diagnostic and prognostic biomarkers: the former detect the occurrence of a disease in subjects suspected of having the disease; the latter are used to predict clinical response in a patient exhibiting disease symptoms. These definitions were proposed in 2001 by the US NIH Biomarkers Definitions Working Group [1] . An alternative classification that is commonly used in cancer research specifies two main types of biomarkers: Predictive and prognostic biomarkers [2] . The former refers to biomarkers used to predict therapeutic responses, and the latter refers to biomarkers for disease classification or risk estimation. In this article we will follow the categorization from the US NIH Biomarkers Definitions Working Group. The discovery of novel biomarkers using different types of 'omic' data has become a crucial goal in translational research. This has been driven in part by their potential to estimate disease states, and also by their potential for aiding in understanding physiological malfunction and in guiding studies in therapeutic development.
At the centre of the biomarker discovery process is the comparison of physiological states or changes across control and disease states [3, 4] . Such differences are reflected in differential molecular activity of gene or protein expression, metabolite profiles and signalling patterns. Thus, in general, those molecular species (i.e. genes, proteins, SNPs, etc.) that account for the most significant changes observed may be defined as potential 'markers' of disease. The traditional approach to applying biomarkers for screening, diagnostic or prognostic purposes has involved the use of a single biomarker and the identification of its 'abnormal' values.
There are three major types of approaches to identifying abnormal biomarker values: Identification based on reference thresholds, based on discrimination thresholds and based on risk thresholds [3] . In the first approach the distribution of biomarker values in a reference group (approximating the general population) is estimated and abnormal values are defined using extreme values on the basis of percentile thresholds. Discrimination thresholds can be defined after comparing the distribution of biomarker values between patient groups (e.g. control versus disease) in terms of their differences. A discrimination threshold aims to maximize the capacity of distinguishing between these groups. The approach based on risk thresholds aims to detect biomarker values that would be associated with a (disease or response) risk increase beyond a critical point on follow-up.
In both traditional and multi-'omic' contexts (next section), significant computational biology contributions relating to the management and understanding of data and information are required ( Figure 3) . One of such fundamental fields deals with the storage (including acquisition and encoding), tracking (including laboratory management systems) and integration of data and information. Integration refers here to 'one-stop' solutions for data access and exchange through either data-warehousing or federated architectures. Partly based on these advances, there are opportunities for more standardized, automated data mining and visualization of clinical and 'omic' data (e.g. genomic variation, gene expression profiles) using a great variety of classic statistical techniques and machine learning. This involves data exploration tools, data clustering, regression and supervised classification [5, 6] . Feature selection [7] through statistical filtering or models 'wrapped' around classifiers, such as neural networks or support vector machines, is an essential component in the biomarker discovery phase. The products of the above tasks may be incorporated into the design of predictive models of disease occurrence or treatment responses, which may require the design, adaptation or combination of different methodologies for static data classification and (time-dependent) survival analyses. More recently, the integration of different types of clinical and 'omic' data has motivated the exploitation of existing biological knowledge or information bases (i.e. functional annotations and curated pathway data) [8] [9] [10] . This, in turn, facilitates the predictive integration of information: the construction of prediction models of disease or treatment response using quantitative evidence extracted from different data sources [6, 11] . All these tasks are now possible thanks to major computational advances accumulated over the past 15 years with regard to information standardization, ontologies for supporting knowledge representation and exchange and data mining. Table 1 categorizes key computational biology areas for biomarker discovery on the basis of their objectives, as well as representative techniques and recently published contributions. The application of machine learning, graph-theoretic and Web-based information retrieval techniques is one of the main drivers of recent and emerging advances in biomarker discovery. However, innovative contributions will be required from the areas of interactive data visualization, extensible software design, open information models and 'network-based' prediction and classification methodologies. Furthermore, there is a need to propose new computational methodologies tailored to application environments characterized by small-sample data sources, highly incomplete or fast-evolving knowledge and dynamic patient record repositories.
OMIC APPROACHES TO BIOMARKER DISCOVERY
The availability of new data sources originating from 'omic' approaches, such as genetic variation and mRNA expression, are allowing a systematic and less biased discovery of novel cardiovascular biomarkers. 'Omic' approaches to biomarker research can be categorized on the basis of: (i) the complexity of the data investigated and (ii) the biological origin of the data.
Under the former scheme, one may define four major types of studies in terms of: (i) the number of biomarkers that are used as inputs to a diagnostic or prognostic model and, (ii) the diversity of these data. Investigations of single biomarkers aim to achieve some predictive or classification ability using a single biomarker, such as a protein concentration value, which could be used to differentiate between disease groups. Studies of multiple biomarkers typically describe a list of different biomarkers with potential diagnostic or prognostic value, which may be used as potential predictors of disease or clinical outcome. Traditional research in this category aims to identify several biomarkers through different statistical analysis (e.g. clustering and functional annotation analysis) in tandem and based on assumptions of biomarker independence. Integrated prediction and classification models combine different biomarkers, which in some cases can be obtained from different experimental methodologies or computational methodologies. This category commonly involves biomarkers representing the inputs to a multi-variable, computational prediction or classification model (e.g. regression, classification). They can also be divided according to the origin and diversity of data: biomarkers originating from the same 'omic' source type, e.g. gene expression only; and biomarkers representing diverse data types of, e.g. gene expression signatures incorporating knowledge from specific biological pathways. Biomarkers studies can also be categorized on the basis of the biological origin of the data analysed. The most important 'omic' domains are: Genomics (e.g. SNPs), transcriptomics, proteomics and metabolomics. Over the past three years there has been a surge of publications reporting a variety of genedisease associations using genomic variation information. A prominent role has been achieved by SNPs identified in candidate gene and genome-wide association studies of common diseases [17] [18] [19] . Biomarkers obtained from transcriptional data include different diagnostic or prognostic signatures using large-scale gene expression data for patient classification and the estimation of treatment responses [20, 21] . Large-scale analyses of the plasma and serum proteomes, as well as metabolite profiling, are offering opportunities for biomarker [15] discovery for risk assessment and patient stratification in different common diseases [22, 23] . More detailed descriptions of these methodologies and medical applications in cancer and cardiovascular research are available in [24] and [25] (cancer research) and [4] (cardiovascular research). Independently of these study categorizations, the biomarker discovery process may be synthesized as a series of iterative experimental and computational steps, as depicted in Figure 5 . Independently of the 'omic' data mining approach applied, the main expected outcomes, from a translational research perspective, are new diagnostic kits (e.g. domainspecific biochips or assays) and computer-based diagnostic and prognostic systems, including documented bio-signatures and computational classifiers. Nevertheless, such outcomes will always depend on the successful implementation of evaluations using independent test samples.
EVALUATING BIOMARKER MODELS
Biomarker model evaluation aims (i) to estimate the real diagnostic or prognostic capability of a model and (ii) to demonstrate its computational and biomedical validity. Model cross-validation and independent validation are the main approaches to achieve such aims. These approaches may use different quantitative indicators of quality, e.g. P-values, sensitivity, specificity and the area under receiver operating curves (AUC).
Cross-validation comprises the selection of disjoint, randomly selected training and testing datasets, which are used for model building (training) and testing independently. Such a sampling process is repeated several times using different, independent training-testing partitions. Overall classification performance is estimated by aggregating the performance indicators originating from the different testing sets. Although the statistical validity of this methodology has been in general established, it is known that classification performance may be overestimated when dealing with very small datasets.
An independent validation consists of the evaluation of a diagnostic or prognostic model on a completely different dataset. Such data should be independently generated from the samples previously used for model cross-validation, i.e. new data are derived from independent experiments. Ideally, different teams independently participate in the data generation and analysis. The patients participating in this validation should be independent from those included in the model construction. Recent studies have stressed the need to implement independent, multicenter validation studies before its use in a clinical setting [26] .
Cross-validation and independent validation may be seen as fundamental, complementary methodologies in biomarker discovery, with the former preceding the latter. The reporting of these and other factors of a biomarker discovery study should be sufficiently clear and detailed to facilitate unbiased interpretation and replication. biomedical research, in general and of diagnostic studies, in particular. The main goal is to ensure that publications present findings in a clear and accurate way to foster their unbiased interpretation and replication [27] . This has been in part motivated by the difficulties often experienced in reproducing scientific findings, e.g. diagnostic biomarkers.
REPORTING BIOMARKER MODELS
The applicability of such recommendations ranges from clinical trials, through systematic reviews of previous research, to the reporting of the quality of diagnostic models ( Table 2 ). The wide acceptance of some of such efforts has led to their adoption as standards for documenting translational biomedical research. One example is the Consolidated Standards of Reporting Trials (CONSORT) [28] , which has been adopted by the scientific community, journals and regulatory organizations involved in clinical trials. This also illustrates how community-based initiatives can promote a greater understanding of the reporting of scientific research, which in turn may positively influence its credibility.
The Standards for Reporting of Diagnostic Accuracy (STARD) are particularly relevant to guide the reporting of biomarker studies [29] . STARD provides researchers with a checklist for ensuring both a transparent and detailed level of reporting. It focuses on specific recommendations for documenting research involving disease classification models, which fit the characteristics described in Figure 4 . Thus, the STARD checklist is divided into major sections reflecting the general organization of a scientific publication (e.g. methods, statistical methods and results). Each section is described by topics that offer specific guidance on 'what' should be reported. The STARD also offers recommendations on graphical documentation of methodologies (i.e. flow diagrams). The STARD statement has already been endorsed by more than 200 scientific journals [30] . Other important guidelines for supporting the reporting of biomarker studies are: the QUADAS (Quality Assessment of Diagnostic Accuracy Studies) tool [31] , the QUORUM (Quality of Reporting of Meta-analyses) guidelines [32] and MOOSE (Metaanalysis Of Observational Studies in Epidemiology) [33] . A summary of the applicability of these community-based recommendations is presented in Table 2 . It indicates when or how these guidelines may be applied and possible relationships. The reader may obtain additional information on these and related initiatives at the EQUATOR Network Web site [34] . EQUATOR is being developed as an umbrella project for promoting the application of reporting guidelines, and for supporting good practice through training activities and online resources.
BIOMARKER MODELS BASED ON INTEGRATED OMIC APPROACHES: FOCUS ON CARDIOVASCULAR BIOMARKERS
Examples of diagnostic biomarkers incorporated into clinical practice include brain natriuretic peptide (BNP) for heart failure, and troponin I and troponin T for myocardial infarction [4] . The capacity of models combining multiple biomarkers to outperform more traditional (molecular or clinical) biomarkers has not been fully demonstrated. For instance, a report from the Framingham Heart Study evaluated the predictive capacity of several molecular markers of death and cardiovascular complications [35, 36] . This investigation concluded that multiple-marker prediction models only add a moderate improvement in prediction performance, in comparison with (single-marker) traditional models. However, this may also be explained by an excessive emphasis placed on classification quality measures such as the AUC.
Another limitation is that the majority of cardiovascular biomarkers may be biased towards wellstudied functional pathways, such as those linked to inflammation and cholesterol synthesis [4] . Moreover, multiple-marker models tend to be based on correlated biomarkers, which may in turn reduce the classification ability of such models. In the data mining and machine learning areas it is well-known that, for classification purposes, the combination of several correlated features is less informative than a combination of fewer uncorrelated (or orthogonal) biomarkers.
Recent advances in the use of multiple biomarkers include the prediction of death from cardiovascular disease in the elderly [37] . In this example, protein expression biomarkers relevant to different functional pathways, such as cell damage and inflammation, improved risk prediction in comparison to traditional clinical and molecular biomarkers, such as age, blood pressure and cholesterol. The proposed and reference models were based on traditional survival analysis during a follow-up period of more than 10 years, and were comparatively evaluated using AUC values. The use of the AUC and other options, such as precision-recall curves, are valid choices for applications in which classification (or discrimination) performance is the main evaluation target. However, the interpretation of diverse performance quality measures is recommended. This, in turn, should be context-specific, e.g. the AUC would not the most suitable choice when risk assessment is the main focus.
The integrated models introduced above mainly fall into the category of integrated prediction models based on homogeneous sources (Figure 4 ). The preferred diagnostic and prognostic model construction methodologies are: Cox proportional-hazards models [17, 38] , in the case of time-dependent prognostic studies and therapeutic response prediction; and different variations of logistic regression for diagnostic classification. Recent applications explore more advanced machine learning approaches such as support vector machine, random forests and neural networks [5, 6, 39] .
In a recent study designed to highlight transcriptomic biomarkers for the prediction of prognosis in patients with new-onset heart failure, Heidecker et al. [40] identified a group of 45 genes providing a prognostic sensitivity of 74% and a specificity of 90%. Although this is a 'preliminary' study due to the low number of patients included in this study (n ¼ 43), this study argues in favour of the ability of transcriptomic analyses to identify powerful groups of biomarkers for the prognosis of heart failure. A significant limitation of this study is that biomarkers have been identified from cardiac biopsies. The assumption that a disease affecting a specific tissue can have a biosignature in blood cells has generated a significant number of studies looking at blood cells expression profiles to determine potential biomarkers. Using whole-genome microarray analysis of blood cells isolated from 41 patients undergoing coronary catheterization, Wingrove et al. [41] identified a set of 14 genes capable to predict the development and extent of coronary artery stenosis. Therefore, transcriptomic biosignatures of blood cells appear to be an affordable and potentially meaningful sample type for biomarker discovery in the cardiovascular field.
Our group also used biosignatures of blood cells to identify potential biomarkers that would aid in the prediction of the development of heart failure after a heart attack. We have investigated the combination of different sources of 'omic' resources, including network-based information, to identify novel prognostic biomarkers of heart failure in patients with myocardial infarction (MI). In one such approach, we assembled a global network of protein-protein interactions (PPI) relevant to key processes and responses in MI, which was used as a knowledge framework to guide subsequent analyses. Thus, for example, we identified highly specialized sub-networks that significantly reduce the search space of potential biomarkers. This information was integrated with large-scale gene expression profiles from the patients to aid in the selection of a relatively short list of potential biomarkers. Additional feature (biomarker) selection enabled the construction of different machine learning classifiers that outperform traditional biomarkers used in routine clinical practice. These approaches not only contribute to a less biased discovery of biomarkers, but also it provides deeper insights into the pathogenesis of diseases and clinical response. For instance, we recently described a transcriptional circuitry reconfiguration leading to poor clinical response after MI based on the combination of a PPI network, gene expression profiles and diseasespecific co-expression networks.
KEY CHALLENGES FOR COMPUTATIONAL BIOLOGY
In general, it is possible to identify two major areas of challenges: Technological and cultural. For example, it will not be possible to fully exploit computational biology advances in the context of translational biomedical research without addressing obstacles relating to information standards, integrated infrastructures and the promotion of interdisciplinary scientific culture.
Other examples of major technological challenges are the relative lack of data together with inconsistent and relatively insufficient statistical analyses. These factors can represent major sources of false positive biomarker predictions [8, 42] . The heterogeneity of sample sources and experimental protocols may also significantly deteriorate predictive performance and validity [8] . There is also a need to assess the predictive power of different integrated multibiomarker systems that can be used to generalise solutions in independent studies and clinical routine. But before that, it is fundamental to implement comparative analyses that include standard biomarker references, e.g. clinical or molecular diagnostic markers routinely used in the hospital.
These and other challenges will not be successfully tackled without the existence of an advanced computational infrastructure that goes beyond the 'single-marker' analysis paradigm. This will require, for example, tools capable to implement data access and analysis in a more integrative fashion, automated work flows and prediction explanatory capabilities. Examples of open-source, integrated tools for the exploration of 'omic' data are the GEPAS [43] and the Weka projects [5] . But there is a need to develop integrated, open tools tailored to biomarker discovery. Also, and despite the availability of 'generic' bioinformatics tools, the cardiovascular and cancer research communities will require extensible and more user-friendly software. This in the long term will facilitate system integration and adaptation to accelerate translational research. Furthermore, the availability of advanced integrated infrastructures, including access to highperformance computing, will fuel the development of novel integrative approaches to discovering 'druggable' targets and disease biomarkers. The availability of emerging 'standards' for sharing, documenting and reporting data and findings will continue improving scientific quality and opportunities for research translation. Bigger investments are required to continue expanding the computational fluency of bioscientists and clinicians. Further discussions on standards for biomarker information sharing and reporting can be found in [27] , and on educational and science policy challenges in [44] .
Meeting technological challenges will not only depend on improving the participation of experienced computational researchers and better funding opportunities. This will also depend on the ability of bioscientists and clinicians to embrace open-minded attitudes toward computational research. On the other hand, there is still a need to support further development of researchers with a computational background to allow them to actively participate in decision making, study design and hypothesis generation activities. Taught graduate courses for students with a primary background in biology should further reinforce problem solving, software development and fundamental mathematical skills. This will not only contribute to the formation of 'good users' of bioinformatic technologies, but also of active supporters of the design of new methods and tools for the systems biology era. Computational biologists, including those focused on the areas of bioinformatics and biostatistics should continue making researchers from other disciplines aware of the importance of their discipline in the knowledge discovery enterprise. This will eventually overcome the 'number crunching' perception of computation biology still prevalent in some sectors of the life sciences.
Although it is evident that an exhaustive review is not possible within the constraints imposed by time and publication space, we hope that this article can provide the reader with some of the fundamental problems, advances and challenges in the area of biomarker discovery. Such advances and challenges should also be seen as new opportunities for making a difference for science and patients all over the world.
Key Points
Computational biology is essential to support the incorporation of fundamental biological knowledge from the laboratory to the clinic. One such contribution is the discovery of novel diagnostic and prognostic biomarkers. Integrated 'omic' biomarkers represent the next generation of diagnostic and prognostic biomarkers. There is a need to promote standard evaluation and reporting practices in biomarker research. Technological problems are not always the main obstacles to progress in translational research: an integrated, cross-disciplinary research culture is crucial.
